Interstitial Lung Disease (ILD): Idiopathic Pulmonary Fibrosis (IPF)
-
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
- Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
- Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- European Respiratory Society/ American Thoracic Society Walking Test Guidelines
- Pulmonary Fibrosis Foundation Educational Resources
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
- Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
- The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung DiseaseDilemmas in Diagnosis and the Conundrum of Treatment
- Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment
- Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium
- Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
- A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis
- Inhaled Treprostinil: Prescribing Information
- Effect of continued treatment with pirfenidone (Nathan SD, et al. Thorax. 2016;71:429-435.)
- Nintedanib Prescribing Information
- Pirfenidone Prescribing Information
- Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
- Diagnosis of IPF: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
- Pulmonary Fibrosis Foundation Patient Education Materials
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
- Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
- Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
- Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
- Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
- Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
- Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
Interstitial Lung Disease (ILD): Sarcoidosis
- ERS clinical practice guidelines on treatment of sarcoidosis
- Repository corticotropin for Chronic Pulmonary Sarcoidosis
Non-Tuberculous Mycobacteria
- Learn about NTM Lung Disease
- ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
- Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
- “INSIGHT” A Patient’s Perspective on NTM
- CDC Clinician Resources on NTM Infection
- Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
- Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study
- NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources
